Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium, taking place February 16-18.In the second interim analysis (IA2) of the MAGNITUDE study, the treatment combination of niraparib and AAP, in comparison to placebo at 26.8 months of median follow-up, demonstrated a statistically significant prolongation in time to symptomatic progression (TSP) and continued consistent improvement of time-to-initiation of cytotoxic chemotherapy (TCC) in the HRR-positive population, and a strong improvement in TSP for the BRCA subgroup of the HRR-positive population. Updated review of the primary endpoints in radiographic progression free survival (rPFS) were consistent with the initial results, which showed a statistically significant benefit in both the HRR-positive population and BRCA subgroup. Additionally, a trend toward improvement in overall survival (OS) was obser...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
More News: Abiraterone Acetate | Allergy & Immunology | Anemia | Biotechnology | Brain | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | Chemotherapy | Clinical Trials | Constipation | Epidemiology | Epithelial Cancer | European Medicines Agency (EMA) | Fallopian Tube Cancer | Gastric (Stomach) Cancer | Gastroschisis Repair | Genetics | Health Management | Heart | Hypertension | Infectious Diseases | International Medicine & Public Health | Japan Health | Learning | Legislation | Liver | Lung Cancer | Marketing | Neurology | Neuroscience | Ovarian Cancer | Ovaries | Pain | Pancreas | Pancreatic Cancer | Peritoneal Cancer | Pharmaceuticals | Prednisolone | Prednisone | Prostate Cancer | Pulmonary Hypertension | Radiography | Science | Statistics | Study | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | WHO